Skip to main content

Table 3 Tissue weight of rats fed HC diets and treated with doses of β-conglycinin, fenofibrate, rosuvastatin and mixtures

From: β-conglycinin combined with fenofibrate or rosuvastatin have exerted distinct hypocholesterolemic effects in rats

 

Dietary groups1

 

HC

HC+7S

HC+FF

HC+RO

HC+7S+FF

HC+7S+RO

Liver weight (g/rat)

13.54 ± 0.36

13.55 ± 0.87

21.10 ± 0.69**

17.07 ± 0.92*

19.32 ± 0.38**

12.83 ± 0.51

Heart (g/rat)

1.03 ± 0.04

0.94 ± 0.03

0.95 ± 0.03

1.26 ± 0.05

0.96 ± 0.02

0.89 ± 0.05

Hepatossomatic índex* (HI)

4.59 ± 0.14

4.41 ± 0.20

7.51 ± 0.27**

5.56 ± 0.27*

6.30 ± 0.12**

4.63 ± 0.16

Heart weight/body weight (g/100 g)

0.34 ± 0.01

0.30 ± 0.02

0.34 ± 0.01

0.41 ± 0.02*

0.33 ± 0.01

0.32 ± 0.01

  1. 1Values are means ± SEM for nine rats. *p < 0.05 and **p < 0.001 by the Bonferroni t-test multiple comparisons versus control group (HC). HC = hypercholesterolemic diet; HC+7S = HC diet + β-conglycinin 300 mg/kg/day; HC+FF = HC diet + fenofibrate 30 mg/kg/day; HC+RO = HC diet + rosuvastatin 10 mg/kg/day; HC+7S+FF = HC diet + β-conglycinin + fenofibrate, 300 and 30 mg/kg/day respectively, and HC+7S+RO = HC diet + β-conglycinin + rosuvastatin, 300 and 10 mg/kg/day respectively. Hepatossomatic índex (HI) = liver weight/body weight × 100.